Redefining Possibilities with Innovative, Effective, and Safe Off-the Shelf Cell Therapies

Vision

At Eterna, our vision is to improve the lives of patients with difficult-to-treat diseases through our innovative, effective, and safe, but accessible cellular therapies.

Mission

Eterna is focused on developing innovative off-the-shelf cellular therapies, leveraging iPSC-derived mesenchymal stem cells (iMSCs) to target solid tumors.

Current Focus & Science

Partner With Us
Currently, we are focusing on developing iPSC-derived MSCs (iMSCs) that express critical factors, such as pro-inflammatory cytokines.
Partner with us
MSCs: Therapeutic Potential and Current Limitations:
...
See More
Induced Pluripotent Stem Cell (iPSC)-derived MSCs (iMSCs)
...
See More
Eterna’s Pro inflammatory Cytokine (e.g. IL-7+IL15) Secreting iPSC-derived MSCs (iMSCs) Therapy
  • Eterna’s iMSC therapy is developed through reprogramming iPSCs using synthetic RNA molecules encoding reprogramming factors
  • The company’s proprietary mRNA-based platform enhances iPSC generation, enabling a scalable, off-the-shelf iMSC product. Our initial iMSC product is designed to deliver IL-7/IL-15 selectively to tumors, limiting systemic exposure and potential toxicity while significantly enhancing T-cell anti-tumor activity.
...
See More

In Development

Eterna will first focus on advancing its lead product candidate ERNA-101, which leverages induced pluripotent stem cells (iPSC)-derived mesenchymal stem cells (iMSCs) over expressing critical factors, such as pro-inflammatory cytokines IL-7 and IL-15 in advanced solid tumors.

Our Collaborations

Watch to learn about our collaboration with Lineage

News

Get In Touch With Us!